Pharmacogenetic prediction of clozapine response

Lancet

Volumn 355, Issue 9215, 2000, Pages 1615-1616

  Arranz, M J ^a   Munro, J ^a   Birkett, J ^a   Bolonna, A ^a   Mancama, D ^a   Sodhi, M ^a   Lesch, K P ^b   Meyer, J F W ^b   Sham, P ^a   Collier, D A ^a   Murray, R M ^a   Kerwin, R W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROTRANSMITTER RECEPTOR; SEROTONIN 2A RECEPTOR;

CLINICAL TRIAL; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NOTE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA;

EID: 0034612110     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02221-2     Document Type: Article

References (5)

1. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenia. a double-blind comparison with chlorpromazine Arch Gen Psychiatr. 45:1988;789-796.
2. Kerwin R.W., Taylor D. New antipsychotics, a review of their current status and clinical potential. CNS Drugs. 6:1996;71-82.
3. 2A receptor gene. Lancet. 346:1995;281-282.
4. 2A receptors and clozapine response. Schiz Res. 32:1998;93-99.
5. Endicott J., Spritzer R.L., Fleiss J.L., Cohen J. The global assessment scale. Arch Gen Psychiat. 1876:55;S5-S12. (suppl).